This is a factual context page for UK users encountering “MHRA approved” or “MHRA regulated” wording on peptide-related clinic, pharmacy, or product pages. It explains what MHRA authorisation actually means, what it does not mean, and how to check product and supply-route claims. It does not assess whether any specific peptide, clinic, pharmacy, or product is safe, legal, suitable, or effective.
The short answer
The MHRA does not “approve peptides” as a category. It authorises individual medicines — specific products with a named active substance, manufacturer, indication, dose form, and marketing authorisation holder — through a formal assessment process. “MHRA approved peptides” is marketing language that can conflate several different situations: a named medicine with an active UK marketing authorisation, a medicine authorised in another jurisdiction but not the UK, a product marketed as a “food supplement” or “research chemical” that has never been through MHRA assessment, or wording that implies a connection to the MHRA that does not exist.
The useful check is the product name, the marketing authorisation number, the authorised indication, and the supply route — not the presence of the phrase “MHRA approved” on a page.
What MHRA authorisation actually means
The Medicines and Healthcare products Regulatory Agency (MHRA) is the UK regulator for medicines and medical devices. When a company wants to place a new medicine on the UK market, it must apply for a marketing authorisation (sometimes still called a product licence). The MHRA assesses the medicine’s quality, safety, and efficacy for a specific use before granting authorisation.
Key points about marketing authorisations:
- Each authorisation covers a specific product — named active substance, brand or trade name, strength, pharmaceutical form, manufacturer, and authorised indication. It does not grant approval to similar molecules, related products, or the same substance made by a different manufacturer.
- The authorisation includes a Summary of Product Characteristics (SmPC) and a Patient Information Leaflet (PIL) — both public documents that set out the authorised uses, doses, contraindications, side effects, and other evidence-based information.
- After authorisation, the product is monitored through the Yellow Card scheme for suspected side effects, quality defects, and safety concerns.
- An authorisation can be suspended, varied, or revoked if new safety or quality information changes the MHRA’s assessment.
A marketing authorisation does not mean the medicine is safe for every person, suitable for every use, or that it has been tested for conditions or patient groups outside its authorised indication. It means the MHRA assessed the evidence submitted by the applicant and judged it sufficient for that specific product and use.
- MHRA: role and work
- MHRA products database (search by product name, active substance, or authorisation number)
- MHRA: marketing authorisation legal status
Why “peptides” wording is misleading
“Peptide” describes a class of molecules — short chains of amino acids. It is not a single substance, a medicine name, or a regulated category. The phrase “MHRA approved peptides” treats a broad chemical class as if it were a single regulated product, which it is not.
Some authorised medicines in the UK are peptides or contain peptide-based active substances — for example, certain GLP-1 receptor agonists such as semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro), and liraglutide (Saxenda, Victoza). These have individual marketing authorisations for specific indications, doses, and routes of administration. But the authorisation applies to the named medicine, not to “peptides” in general.
Products sold as “peptides” for research, cosmetic, or supplement purposes — including those marketed as BPC-157, TB-500, thymosin alpha-1, AOD-9604, or similar names — are not MHRA-authorised medicines in the UK. They have not gone through the marketing-authorisation process, and their quality, safety, and efficacy for any medical use have not been assessed by the MHRA.
How to check a product claim
When a clinic, pharmacy, or online seller uses “MHRA approved” wording, you can check the claim against public sources:
- Search the MHRA products database at products.mhra.gov.uk by the product name, active substance, or marketing authorisation number. If the product has a current UK marketing authorisation, the database entry shows the authorisation holder, legal status (POM, P, GSL), and authorised indication.
- Check the Summary of Product Characteristics (SmPC) and Patient Information Leaflet (PIL) on the MHRA products database or via the electronic Medicines Compendium (eMC). These documents show the authorised uses, doses, contraindications, side effects, and manufacturer details.
- Check the legal status — prescription-only medicine (POM), pharmacy medicine (P), or general sale list (GSL). Most peptide-based medicines for weight management or diabetes are POM, meaning they require a prescription from an appropriate prescriber and supply through a registered pharmacy.
- Separate the product claim from the provider route. Even if a named medicine has a valid UK marketing authorisation, the provider route still needs checking: who assessed you, who prescribed, which pharmacy supplies it, how monitoring and follow-up work, and what the total cost includes.
- MHRA products database
- electronic Medicines Compendium (eMC)
- GOV.UK: check whether a medicine is licensed in the UK
Unlicensed and off-label context
Some peptide-based products used in UK clinics are not MHRA-authorised medicines for their advertised use. This can apply to:
- Unlicensed products — products that have no UK marketing authorisation and are not listed in the MHRA products database. These have not been assessed by the MHRA for quality, safety, or efficacy.
- Specials and unlicensed imports — in limited circumstances, a prescriber may arrange an unlicensed product for a specific patient under their direct responsibility. This route has different legal and regulatory requirements and does not mean the product has been assessed by the MHRA in the same way as an authorised medicine.
- Off-label use — using an authorised medicine outside the terms of its marketing authorisation (for example, prescribing a GLP-1 medicine authorised for diabetes for weight loss in a patient without diabetes). Off-label prescribing is common in some fields but puts greater responsibility on the prescriber and may affect regulatory protections, monitoring, and follow-up.
When a provider advertises a product that is unlicensed or used off-label for the advertised purpose, “MHRA approved” wording is likely to be misleading or incomplete. The check is to identify the exact product, its authorisation status, and the authorised indication — not to rely on the phrase alone.
- MHRA: supply of unlicensed medicines for individual patients
- GMC guidance on prescribing unlicensed or off-label medicines
Advertising claims and regulation
In the UK, advertising of medicines is regulated by the MHRA and enforced by the Advertising Standards Authority (ASA) and the Professional Standards Authority (PSA) for health and social care. Claims that a product is “MHRA approved” when it does not have a current marketing authorisation, or when the wording implies a broader endorsement than the authorisation covers, may breach UK advertising rules.
If you see “MHRA approved peptides” used in a way that appears misleading, you can report it to the ASA. The MHRA also operates the Yellow Card scheme for reporting suspected side effects, quality defects, or counterfeit products.
- Advertising Standards Authority (ASA)
- MHRA Yellow Card scheme
- Report a counterfeit medicine or medical device
Costs and provider checks still matter
Even when a named peptide-based medicine has a valid UK marketing authorisation, the provider route needs the same checks as any clinic or pharmacy. “MHRA approved” wording on a clinic page does not tell you who assessed you, who prescribed the medicine, which pharmacy supplies it, how it is dispensed or delivered, what monitoring and follow-up are included, or what the total cost covers.
Separating the product’s authorisation status from the provider’s care model is the core comparison question. A medicine can be MHRA-authorised for a specific indication while the provider route behind it is unclear, poorly monitored, or more expensive than comparable routes.
“MHRA approved peptides” is a phrase that sounds reassuring but can obscure the real question: which exact product, for which indication, through which supply route, and with which level of assessment, prescribing, pharmacy, monitoring, and follow-up. The useful evidence is the product identity and the route behind it, not the presence of regulator-adjacent wording.
What this page is not
- It is not confirming or denying that any specific peptide product has MHRA authorisation.
- It is not saying authorisation is a guarantee of safety, suitability, or effectiveness for any individual.
- It is not an off-label prescribing, unlicensed medicine, or specials guidance page.
- It is not a provider-ranking, best-clinic, or cheapest-supplier page.
- It is not medical, legal, or regulatory advice.